Upgrade to SI Premium - Free Trial

Amgen's (AMGN) Repatha Trail Met Primary Endpoint in Reducing Risk of Cardiovascular Events

February 2, 2017 4:01 PM
Amgen (NASDAQ: AMGN) today announced that the FOURIER trial evaluating whether Repatha® (evolocumab) reduces the risk of cardiovascular events in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News

Next Articles